Table 2.
Ten years data and change in patient and disease characteristics between baseline and 10 years for orthopaedic shoe users (n = 57) and non-users (n = 228)
| Orthopaedic shoe users | Non-orthopaedic shoe users | p value | |||
|---|---|---|---|---|---|
| N | N | ||||
| BMI (kg/m2) | 56 | 26.7 (4.3) | 208 | 26.6 (4.2) | 0.917 |
| Δ BMI (kg/m2) | 56 | 0.2 (0.3) | 208 | 0.6 (2.5) | 0.304 |
| Smoking (% yes) | 56 | 33.9 | 208 | 22.1 | 0.069 |
| Δ Smoking | 56 | −4.8 | 208 | −7.7 | 0.936 |
| Alcohol consumption (% yes) | 55 | 60.0 | 207 | 63.0 | 0.685 |
| Δ Alcohol consumption | 55 | 3.9 | 207 | 11.6 | 0.551 |
| CRP [median (range)] | 55 | 3 (1; 52) | 210 | 3 (0; 147) | 0.752 |
| Δ CRP | 55 | −15 (−172; 36) | 205 | −16 (−231; 136) | 0.749 |
| DAS | 55 | 1.7 (0.8) | 216 | 1.6 (0.7) | 0.440 |
| Δ DAS | 55 | −2.9 (1.1) | 216 | −2.7 (1.0) | 0.347 |
| Ritchie articular index | 56 | 2.5 (3.6) | 217 | 1.9 (2.5) | 0.064 |
| Δ Ritchie articular index | 56 | −13.2 (7.3) | 216 | −11.5 (6.4) | 0.097 |
| Total SJC | 55 | 1.2 (2.2) | 218 | 1.4 (2.3) | 0.031 |
| Δ Total SJC | 55 | −14.3 (7.4) | 217 | −13.0 (6.9) | 0.222 |
| TJC foot/ankle joints [median (range)] | 56 | 12 (0; 26) | 226 | 10 (0; 30) | 0.053 |
| Δ TJC foot/ankle joints | 53 | −8 (−24; 46) | 210 | −7 (−30; 20) | 0.364 |
| SJC foot/ankle joints [median (range)] | 56 | 6 (0; 16) | 222 | 4 (0; 21) | 0.033 |
| Δ SJC foot/ankle joints | 55 | −5 (−16; 0) | 212 | −3.5 (−21; 7) | 0.076 |
| ESR [median (range)] | 54 | 18.4 (17.4) | 217 | 20.1 (18.0) | 0.337 |
| Δ ESR | 54 | −20.5 (−75; 31) | 217 | −14 (−105; −52) | 0.586 |
| HAQ | 56 | 0.8 (0.7) | 217 | 0.5 (0.5) | 0.005 |
| Δ HAQ | 56 | −0.7 (0.7) | 217 | −0.8 (0.7) | 0.496 |
| VAS pain (mm) | 56 | 23.7 (23.6) | 216 | 19.6 (20.9) | 0.205 |
| Δ VAS pain | 56 | −32.5 (27.8) | 215 | −33.4 (25.1) | 0.809 |
| VAS general health (mm) | 56 | 24.4 (18.8) | 217 | 21.6 (20.9) | 0.368 |
| Δ VAS general health | 56 | −30.59 (26.4) | 217 | −29.4 (25.5) | 0.753 |
| VAS disease activity (mm) | 56 | 24.3 (22.3) | 217 | 20.3 (21.1) | 0.223 |
| Δ VAS disease activity | 56 | −37.68 (28.0) | 216 | −39.0 (27.3) | 0.741 |
| VAS morning stiffness (mm) | 56 | 23.2 (22.7) | 216 | 20.5 (20.8) | 0.382 |
| Δ VAS morning stiffness | 56 | −34.3 (27.3) | 215 | −40.4 (26.7) | 0.135 |
| Patients with erosions (%) | 55 | 75.4 | 225 | 58.8 | 0.020 |
| Δ Patients with erosions | 55 | 35.1 | 225 | 34.7 | 0.593 |
| Total SHS [median (range)] | 49 | 13.5 (0; 146.5) | 206 | 6 (0; 224.5) | 0.003 |
| Δ Total SHS | 47 | 3.5 (0.0; 145.5) | 193 | 2.00 (−1.5; 215.5) | 0.007 |
| Bone erosions | 49 | 4 (0.0; 54.5) | 206 | 1 (0; 98.5) | 0.008 |
| Δ Bone erosions | 47 | 1.5 (0.0; 50) | 192 | 0.05 (−0.05; 97) | 0.009 |
| Bone erosions foot [median (range)] | 51 | 1.5 (0.0; 42.5) | 209 | 0 (0; 32.5) | 0.002 |
| Δ Bone erosions foot | 50 | 1.0 (0.0; 28.5) | 197 | 0.0 (−0.5; 31.0) | 0.002 |
| Bone erosions hands [median (range)] | 51 | 0.5 (0; 37.5) | 208 | 0 (0; 66) | 0.061 |
| Δ Bone erosions hands | 50 | 0.25 (−0.05; 37.5) | 199 | 0.0 (−0.5; 66) | 0.196 |
| JSN [median (range)] | 50 | 8.25 (0.0; 96.5) | 207 | 4 (0; 126) | 0.004 |
| Δ JSN | 48 | 2.75 (−1.5; 95.5) | 195 | 1.0 (−1.5; 118.5) | 0.007 |
| JSN foot [median (range)] | 52 | 2 (0.0; 36) | 210 | 0 (0; 40) | <0.001 |
| Δ JSN foot | 51 | 1.0 (0.0; 36.0) | 200 | 0.0 (0.0; 35.0) | <0.001 |
| JSN hands [median (range)] | 51 | 4.5 (0.0; 60.5) | 208 | 3 (0; 86) | 0.025 |
| Δ JSN hands | 50 | 1.25 (−1.5; 59.5) | 199 | 0.0 (−1.5; 83.5) | 0.037 |
Mean (SD) reported if not stated otherwise
RF rheumatoid factor, ACPA anti-citrullinated protein antibodies, BMI body mass index, CRP c-reactive protein, DAS disease activity score, TJC tender joint count, SJC swollen joint count, HAQ health assessment questionnaire, VAS visual analogue scale, SHS Sharp/van der Heijde score, JSN joint space narrowing